Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (Q33415041)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gunter von Minckwitz

1

0 references

Andreas Schneeweiss

2

object named as

Andreas Schneeweiss

0 references

3

object named as

Sibylle Loibl

0 references

Holger Eidtmann

13

object named as

Holger Eidtmann

0 references

Valentina Nekljudova

25

object named as

Valentina Nekljudova

0 references

26

object named as

Michael Untch

0 references

15

object named as

Jens Huober

0 references

12

object named as

Sherko Kümmel

0 references

Carsten Denkert

object named as

Carsten Denkert

5

0 references

Peter A. Fasching

21

object named as

Peter A Fasching

1 reference

Europe PubMed Central

26 July 2017

author name string

Christoph Salat

4

1 reference

Europe PubMed Central

26 July 2017

Mahdi Rezai

6

1 reference

Europe PubMed Central

26 July 2017

Jens U Blohmer

7

1 reference

Europe PubMed Central

26 July 2017

Christian Jackisch

8

1 reference

Europe PubMed Central

26 July 2017

Stefan Paepke

9

1 reference

Europe PubMed Central

26 July 2017

Bernd Gerber

10

1 reference

Europe PubMed Central

26 July 2017

Dirk M Zahm

11

1 reference

Europe PubMed Central

26 July 2017

Peter Klare

14

1 reference

Europe PubMed Central

26 July 2017

Serban Costa

16

1 reference

Europe PubMed Central

26 July 2017

Hans Tesch

17

1 reference

Europe PubMed Central

26 July 2017

Claus Hanusch

18

1 reference

Europe PubMed Central

26 July 2017

Jörn Hilfrich

19

1 reference

Europe PubMed Central

26 July 2017

Fariba Khandan

20

1 reference

Europe PubMed Central

26 July 2017

Bruno V Sinn

22

1 reference

Europe PubMed Central

26 July 2017

Knut Engels

23

1 reference

Europe PubMed Central

26 July 2017

Keyur Mehta

24

1 reference

Europe PubMed Central

26 July 2017

publication date

30 April 2014

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

15

1 reference

Europe PubMed Central

26 July 2017

747-756

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of treatment effects in subsets of patients in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970160-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70160-3

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33415041&oldid=1966926568"